Marhefka Joie N, Marascalco Philip J, Chapman Toby M, Russell Alan J, Kameneva Marina V
McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Biomacromolecules. 2006 May;7(5):1597-603. doi: 10.1021/bm060014i.
Water-soluble drag-reducing polymers (DRPs) were previously demonstrated to significantly increase blood flow, tissue perfusion, and tissue oxygenation when injected intravenously at nanomolar concentrations in various animal models. Turbulent flow drag-reducing ability was proven to be the most important factor defining the potential of polymers to favorably affect blood circulation. Several DRPs were applied in previous in vivo tests, but the search continues for suitable DRPs for biomedical applications. We demonstrated that poly(N-vinylformamide) (PNVF) with a molecular weight of 4.5 x 10(6) Da significantly reduced resistance to turbulent flow in a pipe and thus presents a DRP. We also found that the PNVF mechanical degradation is much slower than that of the most commonly used DRP, poly(ethylene oxide). PNVF is known to have low toxicity. Furthermore, our pilot in vivo study showed that PNVF had acceptable biocompatibility and hemodynamic effectiveness and thus could be considered as a DRP candidate for potential clinical use.
水溶性减阻聚合物（DRPs）先前已被证明，在各种动物模型中以纳摩尔浓度静脉注射时，能显著增加血流量、组织灌注和组织氧合。湍流减阻能力被证明是决定聚合物对血液循环产生有利影响潜力的最重要因素。先前在体内试验中应用了几种DRPs，但仍在继续寻找适合生物医学应用的DRPs。我们证明，分子量为4.5×10⁶ Da的聚（N-乙烯基甲酰胺）（PNVF）能显著降低管道内的湍流阻力，因此是一种DRP。我们还发现，PNVF的机械降解比最常用的DRP聚环氧乙烷要慢得多。已知PNVF具有低毒性。此外，我们的初步体内研究表明，PNVF具有可接受的生物相容性和血液动力学有效性，因此可被视为潜在临床应用的DRP候选物。
